European neurology · 2019
Role of Muscle Profile in Alzheimer's Disease: A 3-Year Longitudinal Study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Moon Yeonsil, Moon Won-Jin, Kim Jin Ok, Kwon Kyoung Ja, Han Seol-Heui
Аннотация
INTRODUCTION: Many factors are known to affect the rate of cognitive decline; however, studies on clinical outcomes are rare. Muscle profile and their relationship to dementia trajectories have not been extensively investigated. We investigated factors that affect the rate of clinical decline and the usefulness of muscle profiles for predicting the clinical outcomes of patients with Alzheimer's dementia (AD).
OBJECTIVE: Sixty-nine subjects with probable AD were included and several factors that are known to affect the rate of cognitive decline were evaluated.
METHODS: Over a period of 3 years, each subject received an annual evaluation that included a clinical interview and an assessment of their cognitive status as measured by a clinical dementia rating-sum of boxes (CDR-SOB) score. Linear mixed-effects models were used to test for associations between each factor and the -CDR-SOB score over time. These analyses were repeated in a multivariate linear mixed-effects model after adjusting the covariates.
RESULTS: Age, diabetes mellitus, and baseline dementia severity were identified as potential covariates that influence clinical progression. However, a subject's muscle profile was not found to predict dementia progression.
CONCLUSIONS: We expect that early screening and intervention, as well as new drugs with mechanisms of action similar to those of antidiabetic medications, will help patients with dementia maintain their clinical status.
OBJECTIVE: Sixty-nine subjects with probable AD were included and several factors that are known to affect the rate of cognitive decline were evaluated.
METHODS: Over a period of 3 years, each subject received an annual evaluation that included a clinical interview and an assessment of their cognitive status as measured by a clinical dementia rating-sum of boxes (CDR-SOB) score. Linear mixed-effects models were used to test for associations between each factor and the -CDR-SOB score over time. These analyses were repeated in a multivariate linear mixed-effects model after adjusting the covariates.
RESULTS: Age, diabetes mellitus, and baseline dementia severity were identified as potential covariates that influence clinical progression. However, a subject's muscle profile was not found to predict dementia progression.
CONCLUSIONS: We expect that early screening and intervention, as well as new drugs with mechanisms of action similar to those of antidiabetic medications, will help patients with dementia maintain their clinical status.